ATE250417T1 - Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6- isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes - Google Patents

Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6- isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes

Info

Publication number
ATE250417T1
ATE250417T1 AT00949718T AT00949718T ATE250417T1 AT E250417 T1 ATE250417 T1 AT E250417T1 AT 00949718 T AT00949718 T AT 00949718T AT 00949718 T AT00949718 T AT 00949718T AT E250417 T1 ATE250417 T1 AT E250417T1
Authority
AT
Austria
Prior art keywords
treatment
fluoronaphth
amino
isopropylpyrimidines
diseases
Prior art date
Application number
AT00949718T
Other languages
English (en)
Inventor
Gordon Smith Pharmagene Baxter
Richard Anthony Pharmag Borman
Original Assignee
Pharmagene Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918058.0A external-priority patent/GB9918058D0/en
Priority claimed from GB0003228A external-priority patent/GB0003228D0/en
Application filed by Pharmagene Lab Ltd filed Critical Pharmagene Lab Ltd
Application granted granted Critical
Publication of ATE250417T1 publication Critical patent/ATE250417T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00949718T 1999-07-30 2000-07-28 Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6- isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes ATE250417T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9918058.0A GB9918058D0 (en) 1999-07-30 1999-07-30 Compound for treatment of gi disorders
GB0003228A GB0003228D0 (en) 2000-02-11 2000-02-11 Treatment of GI disorders
PCT/GB2000/002907 WO2001008668A2 (en) 1999-07-30 2000-07-28 Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders

Publications (1)

Publication Number Publication Date
ATE250417T1 true ATE250417T1 (de) 2003-10-15

Family

ID=26243634

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00949718T ATE250417T1 (de) 1999-07-30 2000-07-28 Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6- isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes

Country Status (9)

Country Link
EP (1) EP1200093B1 (de)
JP (1) JP2004500333A (de)
AT (1) ATE250417T1 (de)
AU (1) AU776149B2 (de)
CA (1) CA2378710A1 (de)
DE (1) DE60005526T2 (de)
ES (1) ES2208382T3 (de)
GB (1) GB2368524B (de)
WO (1) WO2001008668A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444477B1 (en) 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
AU2003290009A1 (en) * 2002-12-23 2004-07-14 Bayer Healthcare Ag Diagnostics and therapeutics for diseases assosciated with 5-hydroxytryptamine (serotonin) receptor 2b (5-hteb)
WO2005097113A2 (en) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited 5-ht2b receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952331A (en) * 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof

Also Published As

Publication number Publication date
JP2004500333A (ja) 2004-01-08
GB2368524A (en) 2002-05-08
WO2001008668A3 (en) 2001-08-23
DE60005526T2 (de) 2004-07-01
AU776149B2 (en) 2004-08-26
WO2001008668A2 (en) 2001-02-08
DE60005526D1 (de) 2003-10-30
GB0204118D0 (en) 2002-04-10
AU6299300A (en) 2001-02-19
EP1200093A2 (de) 2002-05-02
EP1200093B1 (de) 2003-09-24
GB2368524B (en) 2003-10-15
CA2378710A1 (en) 2001-02-08
ES2208382T3 (es) 2004-06-16

Similar Documents

Publication Publication Date Title
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
CY1113306T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE69922914D1 (de) Stimulationssystem zur Behandlung von Erkrankungen bezüglich des Magenspeiseröhrenreflux
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019195D1 (de) Behandlung durch Ablation von Knochenmetastasen
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60325377D1 (de) Motilidverbindungen
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
ATE250417T1 (de) Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6- isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
TR200200278T2 (tr) Kalsilitik bileşimler
DE60211495D1 (de) Xanthin-glycol-derivate zur behandlung des reizdarmsyndroms
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties